Theriva(TM) Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
Theriva(TM) Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results GlobeNewswire August 11, 2025 – Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October – – VCN-01 demonstrates potential in retinoblastoma with […]